AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 252 min read$RPRX

Urist Marshall sold $502K of RPRX

Urist Marshall (EVP, Research & Investments) sold 9,098 shares of Royalty Pharma plc (RPRX) at $55.18 ($0.50M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Urist Marshall
Published Jun 25, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RPRX
Neutral
medium confidence
Mentioned
$RPRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RPRXNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new company fundamentals; any trading impact is likely limited to short-term sentiment.

02

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 framing reduces the signal strength.

03

What to watch

The net effect depends on whether this sale is part of a larger, repeated pattern; this article provides only one transaction and no context on prior/aggregate insider activity.

Relevance 4/10Novelty 3/10Timing: after-hours/filing update (Form 4 filed 2026-06-25)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Royalty Pharma plc.

Company-level read

Ticker impact

$RPRXNeutralMedium confidence
Context

Royalty Pharma EVP Urist Marshall filed an open-market sale of 9,098 shares at $55.1843 on 2026-06-24 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it provides no new operational, financial, or regulatory information about Royalty Pharma.

Market effects

Sector

Minimal; insider-sale disclosures typically do not reset sector expectations without accompanying company catalysts.

Regional

Minimal; no broader market or regional linkage is provided.

Global

Minimal; the event is company-specific and does not reference global developments.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish conviction.

Key entities

  • issuer
    Royalty Pharma plc

    Company whose officer transaction is disclosed on SEC Form 4.

  • insider
    Urist Marshall

    EVP, Research & Investments; reported an open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RPRX insider trading history →

Related articles

SEP 10
$RPRXMedAI 8/10

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Royalty Pharma (RPRX) reported that pelacarsen failed its Phase 3 trial, shifting financial focus to Spinraza royalties. The company provided $500M to Ionis (IONS) in 2023, with $150M allocated to pelacarsen. RPRX expects to recover its investment through Spinraza, aiming for a modest return. The failure limits pelacarsen's potential upside, and recovery depends on Spinraza's performance.

insidermonkey.com2 min
SEP 8
$NVSHighAI 8/10

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Novartis AG (NYSE:NVS) stock fell sharply after its Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed the primary endpoint. The company also reported that the pelacarsen Phase 3 Lp(a)HORIZON trial for cardiovascular outcomes failed. Both Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) saw stock declines due to their ties with Novartis.

aol.com2 min
SEP 8
$NVSHighAI 8/10

Why Is Novartis Stock Falling Today? - Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty

Novartis (NYSE:NVS) stock fell sharply after Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed primary endpoint. The company also reported that the pelacarsen cardiovascular trial failed to meet its primary endpoint. Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) shares also declined due to the trial results. Novartis is evaluating the data and plans to discuss next steps with health authorities.

benzinga.com2 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min
SEP 1
$RPRXMedAI 8/10

Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough

Royalty Pharma (RPRX) agreed to pay Zealand Pharma $100M for future royalties on rusfertide, an experimental treatment for polycythemia vera. The deal includes a 1% royalty on global sales, with $50M paid at closing and the rest after a year. Rusfertide's FDA decision is expected in Q3 2026. RPRX's Q2 2026 royalty receipts grew 14% to $768M, and it raised its full-year guidance to $3.4B-$3.5B. The company has $9.2B in debt and expects $350M-$360M in interest payments for 2026.

insidermonkey.com2 min